Meeting
2021 ASCO Annual Meeting
Complete responders to checkpoint inhibitors in advanced melanoma: Relapse risk factors, and patients' outcomes.
Authors
Amelie Dutheil
Dermatology Unit, Gustave Roussy Cancer Institute, Villejuif, France
Amelie Dutheil , Djaouida Belkadi , Marine Antigny , Severine Roy , Jeremy Lupu , Anaïs Vallet , Emilie Routier , Caroline Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9550)
DOI
10.1200/JCO.2021.39.15_suppl.9550
Abstract #
9550
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.
First Author: Lili Mao
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh
Poster
2014 ASCO Annual Meeting
Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple oncogenic pathways.
First Author: Alexandra Leary
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini